Just to reiterate what RMM said: Is Tim really going to stand up and sing the praises of 1801 in Covid, after 6 months of investigation if it’s not been successful? Apart from the embarrassment the damage to his and sareum reputation would be huge.
In his presentation, Dr Mitchell will showcase Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801 targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections, and SDC-1802 targeting cancers.